This post has been archived and contains information that may be out of date.
The Food and Drug Administration (FDA) has amended emergency use authorization (EUA) for COVID-19 vaccines to allow booster doses for the Moderna and Johnson & Johnson vaccines. Specifically, the EUA allows for a single-dose booster in the following circumstances:
- The use of a single booster dose of the Moderna COVID-19 vaccine may be administered at least six months after completion of the primary series to individuals:
- Ages 65 and older
- Ages 18-64 at high risk of severe COVID-19
- Ages 18-64 with frequent institutional or occupational exposure to SARS-CoV-2
- The use of a single booster dose of the Johnson & Johnson COVID-19 vaccine may be administered at least two months after completion of the single-dose primary regimen to individuals ages 18 older.
The FDA also authorizes a heterologous (or “mix and match”) booster dose in eligible individuals following completion of primary vaccination with a different available COVID-19 vaccine.
